- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
SinoMab BioScience Ltd (3681)
Track the SinoMab BioSci share price today and view real-time 3681 share price data, including charts, technicals, and key financials. View the 3681 premarket stock price ahead of the market session or assess the after hours quote. Explore 3681 stock price movements, trading volume, and market activity across the HK exchange.
What Is the SinoMab BioSci Stock Price Today?
The SinoMab BioSci stock price today is 1.50.
What Is the Stock Symbol for SinoMab BioSci?
The stock symbol for SinoMab BioSci is ""3681.""
What Stock Exchange Does SinoMab BioSci Trade On?
SinoMab BioSci is listed and trades on the Hong Kong stock exchange.
Is SinoMab BioSci a Good Stock to Buy?
Determining whether SinoMab BioSci or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 3681 quote. (ISIN: HK0000544194)
What Is the SinoMab BioSci Stock Price Today?
The SinoMab BioSci stock price today is 1.50.
What Is the Stock Symbol for SinoMab BioSci?
The stock symbol for SinoMab BioSci is ""3681.""
What Stock Exchange Does SinoMab BioSci Trade On?
SinoMab BioSci is listed and trades on the Hong Kong stock exchange.
Is SinoMab BioSci a Good Stock to Buy?
Determining whether SinoMab BioSci or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 3681 quote. (ISIN: HK0000544194)
Hong Kong
Currency in HKD
1.50
-0.03(-1.96%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.49
1.55
52 wk Range
1.16
3.76
3681 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.491.55
52 wk Range
1.163.76
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
3681 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Operates with a moderate level of debt
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell
Earnings
Latest Release
23/03/2026
EPS / Forecast
-0.04 / --
Revenue / Forecast
-9.78M / --
Compare 3681 to Peers and Sector
Metrics to compare | 3681 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship3681PeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.3x | −32.3x | −0.5x | |
PEG Ratio | −0.35 | 0.07 | 0.00 | |
Price/Book | 3.6x | 5.7x | 2.6x | |
Price / LTM Sales | 633.1x | 15.3x | 3.2x | |
Upside (Analyst Target) | - | 31.8% | 48.8% | |
Fair Value Upside | Unlock | −0.2% | 6.9% | Unlock |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus. In addition, the company is developing SM06, a humanised Anti-CD22, that is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren’s syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin’s lymphoma and autoimmune diseases. Further, it develops Anti-CGC antibody, which is in preclinical trial to treat vitiligo and alopecia areata; and Bispecific antibody candidate (bsAb), which is in preclinical trial to treat osteoporosis. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the SinoMab BioSci (3681) Stock Price Today?
The SinoMab BioSci stock price today is 1.50 HKD.
What Stock Exchange Does SinoMab BioSci Trade On?
SinoMab BioSci is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for SinoMab BioSci?
The stock symbol for SinoMab BioSci is "3681."
What Is the SinoMab BioSci Market Cap?
As of today, SinoMab BioSci market cap is 2.08B HKD.
What Is SinoMab BioSci's Earnings Per Share (TTM)?
The SinoMab BioSci EPS (TTM) is -0.09.
From a Technical Analysis Perspective, Is 3681 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has SinoMab BioSci Stock Split?
SinoMab BioSci has split 0 times.
How Many Employees Does SinoMab BioSci Have?
SinoMab BioSci has 61 employees.
What is the current trading status of SinoMab BioSci (3681)?
As of 01/05/2026, SinoMab BioSci (3681) is trading at a price of 1.50 HKD, with a previous close of 1.53 HKD. The stock has fluctuated within a day range of 1.49 HKD to 1.55 HKD, while its 52-week range spans from 1.16 HKD to 3.76 HKD.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.